Cingulate

Cingulate EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Cingulate (CING) as of Nov 11, 2026 is -21.09 M USD. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -15.64 M USD — a change of 34.80% (lower).

EBITDA

-21.09 MUSD

YoY

34.80%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Cingulate is 2025 -21.09 M USD. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Cingulate was 2024 -15.64 M USD. It decreases by 34.80% lower compared to the previous year.

The Cingulate EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2019
-11.65 M USD
Jan 1, 2020
-7.08 M USD
Jan 1, 2021
-20.68 M USD
Jan 1, 2022
-17.50 M USD
Jan 1, 2023
-22.77 M USD
Jan 1, 2024
-15.64 M USD
Jan 1, 2025
-21.09 M USD
The Cingulate EBITDA history
YEAREBITDAYoY
-21.09 MUSD+34.80%
-15.64 MUSD-31.28%
-22.77 MUSD+30.08%
-17.50 MUSD-15.37%
-20.68 MUSD+191.94%
-7.08 MUSD-39.18%
-11.65 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cingulate Stock analysis

What does Cingulate do? Cingulate Inc is a US-based biopharmaceutical company headquartered in Kansas City, Kansas, that focuses on the development, manufacturing, and commercialization of pharmaceutical products. The firm utilizes its precision timed release (PTR) drug delivery platform technology to create dosing schedules and drug release profiles designed to improve the lives of patients suffering from commonly diagnosed conditions. The company specifically targets the treatment of attention deficit/hyperactivity disorder (ADHD) through its innovative approach to drug delivery. The firm is currently developing two lead product candidates, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine). These drug candidates both contain three releases of an active pharmaceutical ingredient combined into one small tablet dosage form. By employing this technology, Cingulate Inc aims to provide effective treatment options for ADHD across three core patient segments: children aged 6-12, adolescents aged 13-17, and adults aged 18 and older. Cingulate is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cingulate stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Cingulate is -21.09 M USD in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Cingulate changed from -15.64 M USD to -21.09 M USD, representing a 34.80% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Cingulate since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Cingulate historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Cingulate

All Key Metrics — Cingulate